Aggressive Angiomyxoma of Vulva in Young Female: A Rare Case Report

Aim/Background: Aggressive angiomyxoma is a rare and benign mesenchymal stromal tumour predominantly occurring in vulvovaginal, pelvis and perineal regions in young females. The tumour has very high risk of local recurrences with a low likelihood of metastasis. Because of its rarity It is usually mi...

Full description

Saved in:
Bibliographic Details
Published inInternational Journal For Multidisciplinary Research Vol. 6; no. 2
Main Authors -, Pulkit Agarwal, -, Siddhartha Verma
Format Journal Article
LanguageEnglish
Published 30.04.2024
Online AccessGet full text

Cover

Loading…
More Information
Summary:Aim/Background: Aggressive angiomyxoma is a rare and benign mesenchymal stromal tumour predominantly occurring in vulvovaginal, pelvis and perineal regions in young females. The tumour has very high risk of local recurrences with a low likelihood of metastasis. Because of its rarity It is usually misdiagnosed. Materials & Methods: We report here a rare case of 32-years-old female patient who presented with slow growing swelling on the right sided labia majora for the last 1 year. USG revealed hypoechoic lesion in vulvar region reaching upto the right pararectal region. Patient had undergone surgery for the tumour. Histopathology report was indicative of Aggressive Angiomyxoma of Vulva. Results: After taking informed and written consent. Wide local excision of the mass and surrounding margins was done under anaesthesia. Patient had undergone Hormonal therapy with GnRH injections (Leuprolide) post-surgery. Her postoperative recovery was uneventful. No complications and recurrence was noted on regular visit to Outdoor patient department uptill now. Conclusion: Aggressive angiomyxoma is a benign and aggressive mesenchymal stromal growth affecting Pelvic and External genital region of young females. Surgical excision is the treatment of choice, but the tumour carries a high risk of recurrence after complete excision. Hormonal Therapy plays a key role in preventing recurrence. A long-term surveillance should be done for a period of at least 12 months post-surgery for the detection of any recurrence.
ISSN:2582-2160
2582-2160
DOI:10.36948/ijfmr.2024.v06i02.19071